AstraZeneca: won't profit from COVID-19 vaccine in pandemic

FILE - In this Saturday, July 18, 2020 file photo a general view of AstraZeneca offices and the corporate logo in Cambridge, England. Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. "We are seeing good immune response in almost everybody," said Dr. Adrian Hill. Hill said Oxford has partnered with drugmaker AstraZeneca to produce their vaccine globally, and that the company has already committed to making 2 billion doses. (AP Photo/Alastair Grant, File)
FILE - In this Saturday, July 18, 2020 file photo a general view of AstraZeneca offices and the corporate logo in Cambridge, England. Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. "We are seeing good immune response in almost everybody," said Dr. Adrian Hill. Hill said Oxford has partnered with drugmaker AstraZeneca to produce their vaccine globally, and that the company has already committed to making 2 billion doses. (AP Photo/Alastair Grant, File)
DANICA KIRKA

LONDON (AP) — Pharmaceutical company AstraZeneca repeated its promise not to profit from a COVID-19 vaccine during the pandemic as it reported it was on track with late-stage trials for the treatment.

Such promises were boosted by strong sales across its range of treatments during lockdown. Sales jumped by 14% to $12.6 billion in the first six months of 2020 and were helped by strong trading in new medicines, as well as cancer and respiratory medication.

Despite the good earnings, CEO Pascal Soriot said he remained cautious amid the uncertainty of the pandemic.

“If we have learned one thing with this virus, it is that it is unpredictable,’’ he said. “And so we need to remain cautious.”

He said the supply chain was on track to make 2 billion doses of the vaccine at a few dollars a dose. It also concluded three more deals for distribution — should the vaccine work.

“We felt, there (is) a time in life when companies need to step up and make a contribution,’’ he said, adding that a vaccine needed to be accessible to as many people as possible.

“This is the kind of time in history when ... humankind is really threatened as a whole,’’ he said.

The cost of making the vaccine, which was developed by Oxford University, is expected to be offset by funding from the governments.

AstraZeneca has struck a number of deals around the world to supply the experimental COVID-19 vaccine, which has shown promise in early testing. The Anglo-Swedish company recently completed agreements with the United States, Britain, the European Union, the Coalition for Epidemic Preparedness Innovations, a public-private-charitable partnership based in Norway, and Gavi, the Vaccine Alliance, another public-private partnership headquartered in Geneva.

It has also reached a licensing agreement with Serum Institute of India to supply low-and-middle-income countries and agreements with R-Pharm in Russia and SK Biopharmaceuticals Co., Ltd in the Republic of Korea “to manufacture and export for other global markets."

“We want to cover the whole world,'' Soriot said, “so everyone can get access to this vaccine.''

More From

  • Ohtani homers, Bundy brilliant as Angels top Mariners 6-1

    Shohei Ohtani homered in his first plate appearance since being shut down as a pitcher, Dylan Bundy struck out 10 in the third complete game of his career and the Los Angeles Angels beat the Seattle Mariners 6-1 on Thursday. Ohtani drove a 1-0 pitch from Seattle starter Taijuan Walker to the opposite field just beyond the leap of left fielder Dee Gordon leading off the second inning. It was Ohtani’s third home run of the season, all coming against the Mariners.

  • Astros' Emanuel banned 80 games for performance enhancer

    Houston Astros left-hander Kent Emanuel has been banned 80 games without pay by Major League Baseball for violating the league's drug prevention and treatment plan. Emanuel has pitched at Triple-A the past three seasons but never in the majors. Emanuel tested positive for Dehydrochlormethyltestosterone (DHCMT), a performance-enhancing substance.

  • Suns win 4th straight bubble game, top Pacers 114-99

    Deandre Ayton had 23 points and 10 rebounds, and the Phoenix Suns continued their improbable run in the NBA bubble on Thursday, beating the Indiana Pacers 114-99 for their fourth straight win. Devin Booker added 20 points and 10 assists and Cameron Johnson had 14 points and 12 rebounds as the Suns pulled away with a 21-0 run that bridged the end of the the third quarter and the start of the fourth. Malcolm Brogdon had 25 points, six assists and six rebounds to lead the Pacers, who fell to 3-1 in Orlando.

  • Anaheim Ducks re-sign D Larsson to 2-year, $2.4 million deal

    The Anaheim Ducks have re-signed defenseman Jacob Larsson to a two-year, $2.4 million deal. The Ducks announced the return of their restricted free agent Thursday. Larsson will make $1.1 million next season and $1.3 million in the 2021-22 campaign.